Bausch + Lomb licenses Stada and Xbrane's Lucentis biosimilar
Eye health specialist Bausch + Lomb, part Bausch Health Companies (TSX: BHC), has entered into an exclusive licensing agreement with Germany’s Stada Arzneimittel (SAZ: Xetra) and its development partner, Sweden’s Xbrane Biopharma (Nasdaq: XBRANE), to commercialize in the USA and Canada a biosimilar candidate to Lucentis (ranibizumab) that is currently in development.
The companies aim to obtain all currently approved indications for Swiss pharma giant Novartis’ (NOVN: VX) Lucentis in both the USA and Canada.
Stada and Xbrane will be jointly responsible for finalizing development of the biosimilar, currently known as Xlucane. Xbrane, whose shares gained 11.85% to 47.20 Swedish kronor on the news, will also provide commercial supply. Bausch + Lomb will be responsible for the sales, marketing and all other commercialization efforts for the biosimilar candidate in the USA and Canada following regulatory approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze